- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Biocristin AQ, Cytocristin, Unicristin, Biocristin
Synonyms :
22-oxovincaleukoblastin, 22-oxovincaleukoblastine, leurocristine, vincristin, vincristina, vincristine, vincristinum
Class :
Antineoplastic agents and Vinca Alkaloid
Dosage Forms & Strengths
Injectable solution
1mg per ml
1.4
mg/m^2
Intravenous (IV)
over one minute once a week
1.4
mg/m^2
Intravenous (IV)
over one minute once a week
Use:
Acute leukemia
This drug shows significant use when combined with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas, and Wilms' tumor.
Comment:
The manufacturer recommends the dose.
Dosage Forms & Strengths
Injectable solution
1mg per ml
The recommended dose for <18 years and <10 kg :
0.05
mg/kg
Intravenous (IV)
over one minute once a week as an initial dose
2 mg/m2 IV given over one minute once a week as the maximum dose
The recommended dose for<18 years and >10 kg: 1-2 mg/m2 IV given over one minute once a week
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased effect of immunosuppressive activities of fingolimod
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased therapeutic efficacy of the measles virus vaccine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased level of serum concentration of vincristine
when both drugs are combined, there may be a decreased therapeutic efficacy of the rotavirus vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased therapeutic efficacy of the smallpox vaccine
when both drugs are combined, there may be a reduced excretion rate of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of peripheral neuropathy
the effect of vincristine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased effect of immunosuppressive activities of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased level of serum concentration of vincristine
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased effect of immunosuppressive activities of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may diminish the excretion rate when combined with vinca alkoloids, resulting in an enhanced serum level
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of nerve damage
may enhance the immunosuppressive effects of each other
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of myopathy, rhabdomyolysis, and myoglobinuria
Frequency defined
>10%
Alopecia
Frequency Not Defined
Acute uric acid nephropathy
Aspermia
Amenorrhea
Constipation
Gait changes
Hypertension
Hypotension
Jaw pain
Loss of deep-tendon reflexes
Myelosuppression
Nausea
Peripheral neuropathy
Paresthesia
Paralytic ileus
Leukopenia
Sensory loss
Vomiting
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pronunciation: vin-kri-sti-n
Use: It is an anti-cancer agent used to treat acute leukemia, Hodgkin’s disease, non-Hodgkin’s disease, rhabdomyosarcoma, and neuroblastoma.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
